The purpose of the study was to analyze changes in some indicators of hospitalization, hemostasis and procalcitonin, to determine the relationship between the level of D-dimer, platelets, international normalized ratio, procalcitonin and time of hospitalization and unfavorable prognosis in patients with acute respiratory disease COVID-19 with diabetes and without diabetes mellitus. Materials and methods. The study included 125 patients with acute respiratory viral disease COVID-19. The group with diabetes mellitus included 52 patients, the group without diabetes – 73. The information obtained from medical records contained demographic data, data on comorbidities, symptoms, treatment, nosocomial complications, laboratory results (including D-dimer, platelets, international normalized ratio, procalcitonin). All patients received treatment according to the protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)" #1979 dated 20.09.21. Results and discussion. The hospitalized patients with concomitant diabetes mellitus were significantly younger (p = 0.001), and the percentage of males was higher than in the comparison group. Among the patients in both groups, the percentage of comorbid cardiovascular disease (hypertension and coronary heart disease) had no significant differences. The rates of hospitalization in the intensive care unit and the mortality rate in the group of patients with diabetes were significantly higher (p = 0.03 and p = 0.02). The shorter period of hospitalization in the main group of patients (p = 0.006) can be explained by the higher mortality rate of this contingent. Indicators of D-dimer in patients with COVID-19 significantly exceeded the reference values. In our study, the indicators of D-dimer showed a tendency to increase in the group of concomitant diabetes mellitus. The rates of hospitalization in the intensive care unit and the mortality rate in the group of patients with diabetes were significantly higher (p = 0.03 and p = 0.02), although the duration of hospitalization was lower in the group of patients with diabetes (p = 0.006). Platelet levels in the same group were significantly lower (p = 0.03), and thrombocytopenia with high D-dimer was associated with mortality. We found a strong direct correlation between D-dimer, procalcitonin and mortality (r = 0.72, and r = 0.75, respectively), and the mean level of D-dimer in the main group of patients who did not survive the disease was significantly higher than of those who recovered. Conclusion. Patients with acute respiratory viral disease COVID-19 on the background of diabetes have a more severe course of the disease and a worse prognosis compared with those who do not have impaired glycemia. Determination of platelet, D-dimer and procalcitonin levels are reliable parameters for assessing the course of the disease and predicting mortality in patients with COVID-19, especially in conditions of comorbidity with diabetes

Keywords: acute respiratory viral disease COVID-19, diabetes mellitus, coagulopathy, D-dimer, platelets

Full text: PDF (Ukr) 254K

1. WHO. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019
2. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle Region - Case series. N Engl J Med. 2020 May 21;382(21):2012-2022. PMID: 32227758. PMCID: PMC7143164. https://doi.org/10.1056/NEJMoa2004500
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3
4. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020 Jul 10;8:49. PMID: 32665858. PMCID: PMC7348129. https://doi.org/10.1186/s40560-020-00466-z
5. Hashem MK, Khedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Hassany SM, et al. Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-dimer. Egypt J Bronchol. 2021;15:29. PMCID: PMC8139548. https://doi.org/10.1186/s43168-021-00075-w
6. Delshad M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Poopak B, Shokouhi S, Bashash D, et al. Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity. Int Immunopharmacol. 2021 Oct;99:107995. PMID: 34304001. PMCID: PMC8295197. https://doi.org/10.1016/j.intimp.2021.107995
7. Comer SP, Cullivan S, Szklanna PB, Weiss L, Cullen S, Kelliher S, et al. COVID-19 induces a hyperactive phenotype in circulating platelets. PLoS Biol. 2021;19(2):e3001109. PMID: 33596198 PMCID: PMC7920383. https://doi.org/10.1371/journal.pbio.3001109
8. Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology. 2021;88(1):15-27. PMID: 33049751. PMCID: PMC7649697. https://doi.org/10.1159/000512007
9. Ming DK, Myall AC, Hernandez B, Weiße AY, Peach RL, Barahona M, et al. Informing antimicrobial management in the context of COVID-19: understanding the longitudinal dynamics of C-reactive protein and procalcitonin. BMC Infect Dis. 2021Sept 08;21:932. PMID: 34496795. PMCID: PMC8424157. https://doi.org/10.1186/s12879-021-06621-7
10. Zhou W, Ye S, Wang W, Li S, Hu Q. Clinical Features of COVID-19 Patients with Diabetes and Secondary Hyperglycemia. J Diabetes Res. 2020 Aug 24;2020:3918723. PMID: 33062712. PMCID: PMC7545437. https://doi.org/10.1155/2020/3918723
11. Trybrat TA, Kazakov YuM, Honcharova OO, Shutʹ SV, Sakevych VD. Perebih hostroyi respiratornoyi khvoroby COVID-19 uskladnenoyi nehospitalʹnoyu pnevmoniyeyu na tli patolohiyi sertsevo-sudynnoyu systemy [The course of acute respiratory disease COVID-19 complicated by community-acquired pneumonia on the background of pathology of the cardiovascular system]. Problemy ekolohiyi i medytsyny. 2021;25(3-4):14–17. [Ukrainian]. https://doi.org/10.31718/mep.2021.25.3-4.03
12. Tronko M, Popova V. COVID-19 i tsukrovyy diabet: novitni dosyahnennya u vyvchenni pytanʹ kliniky y terapiyi [COVID-19 and Diabetes: Recent Advances in Clinical Therapy]. Praktykuyuchyy likar. 2021;(2):13-23. [Ukrainian]
13. Moin ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, Butler AE. Platelet Protein-Related Abnormalities in Response to Acute Hypoglycemia in Type 2 Diabetes. Front Endocrinol (Lausanne). 2021 Mar 30;12:651009. PMID: 33859620. PMCID: PMC8043308. https://doi.org/10.3389/fendo.2021.651009
14. Calvisi SL , Ramirez GA, Scavini M, Prat VD, Di Lucca G, Laurenzi A, et al. Thromboembolism risk is higher among patients with diabetes and COVID-19 and is associated to poor clinical outcome. medRxiv. 2021.04.17.21255540. https://doi.org/10.1101/2021.04.17.21255540
15. Miri C, Charii H, Bouazzaoui MA, Laouan Brem F, Boulouiz S, Abda N, et al. D-dimer Level and Diabetes in the COVID-19 Infection. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211045902. PMID: 34590493. PMCID: PMC8495508. https://doi.org/10.1177/10760296211045902
16. Nakaz MOZ Ukrayiny vid 20.09.2021 № 1979. Pro vnesennya zmin do protokolu «Nadannya medychnoyi dopomohy dlya likuvannya koronavirusnoyi khvoroby (COVID-19)» [On amendments to the protocol "Provision of medical care for the treatment of coronavirus disease (COVID-19)"]. [Ukrainian]. Available from: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-20092021--1979-pro-vnesennja-zmin-do-protokolu--nadannja-medichnoi-dopomogi-dlja-likuvannja--koronavirusnoi-hvorobi-covid-19
17. Tsukrovyy diabet 2 typu: Unifikovanyy klinichnyy protokol pervynnoyi ta vtorynnoyi (spetsializovanoyi) medychnoyi dopomohy [Type 2 diabetes mellitus: Unified clinical protocol of primary and secondary (specialized) medical care]. K; 2012. 115 s. [Ukrainian]
18. Tsukrovyy diabet 1 typu u molodykh lyudey ta doroslykh : Unifikovanyy klinichnyy protokol pervynnoyi, ekstrenoyi, vtorynnoyi (spetsializovanoyi) ta tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy (UKPMD) [Type 1 diabetes mellitus in young people and adults: Unified clinical protocol of primary, emergency, secondary (specialized) and tertiary (highly specialized) medical care]. K; 2014. 71 s. [Ukrainian]
19. McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020 Jul;2(7):e437–45. https://doi.org/10.1016/S2665-9913(20)30121-1
20. Zhao X, Wang K, Zuo P, Liu Y, Zhang M, Xie S, et al. Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach. EPMA J. 2020 May 14;11(2):1-7. PMID: 32419876. PMCID: PMC7224348. https://doi.org/10.1007/s13167-020-00208-z
21. Elemam NM, Hannawi H, Salmi IA, Naeem KB, Alokaily F, Hannawi S. Diabetes mellitus as a comorbidity in COVID-19 infection in the United Arab Emirates. Saudi Med J. 2021 Feb;42(2):170-180. PMID: 33563736. PMCID: PMC7989288. https://doi.org/10.15537/smj.2021.2.25700